Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting
Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…Abstract Number: 2407 • 2018 ACR/ARHP Annual Meeting
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The most often prescribed biologics…Abstract Number: 2298 • 2017 ACR/ARHP Annual Meeting
Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with onset before 16 years of age, that persists for at least 6 weeks, and has…Abstract Number: 416 • 2016 ACR/ARHP Annual Meeting
Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Approximately 10-15% of patients (pts) with juvenile idiopathic arthritis (JIA) experience comorbid uveitis. The objective of this study is to explore events of uveitis and…Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting
The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…